ArticleFrontiers in oncology2023

RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03).

Feng Wen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.